Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES CFO TRANSITION

Luc Mainville will be leaving his position as chief financial officer of LSL Pharma Group Inc., effective immediately.

LSL Pharma has initiated a formal search process for a new chief financial officer and will provide further updates as appropriate. In the interim, president and chief executive officer Francois Roberge will temporarily assume the CFO role, supported by a solid financial team, with continued oversight from the audit committee, chaired by Mario Paradis.

"On behalf of the board of directors and the management team, I would like to thank Luc for his contribution to LSL Pharma," said Mr. Roberge, president and chief executive officer of LSL Pharma. "We wish him well in his future endeavours.

"LSL Pharma's operations and strategic priorities remain unchanged, and the management team continues to focus on the execution of our growth strategy across all our businesses," concluded Mr. Roberge.

About LSL Pharma Group Inc.

LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Sante Inc., Dermolab Pharma Ltd., Du-Var Laboratory Inc. and LSL MedPlus Inc. (formerly Juno OTC Inc.).

We seek Safe Harbor.